Medical News / From ASH Meeting 2019, CC-486 Could Represent New Therapeutic Standard for AML Patients

Results of a phase 3 study presented at the American Society of Hematology (ASH) 2019 annual meeting indicate a novel oral therapy could be the first maintenance therapy to provide significant and meaningful improvements in overall survival (OS) and relapse-free survival (RFS) in patients with acute myeloid leukemia (AML) in remission. Source: MDMag. By reading more or clicking on the link below, you are leaving this site and going to another site run by another organization.

read more

Beaumont Health’s 29th Annual Cardiovascular Conference in Beaver Creek, CO, this February built on its own ... read more
The 29th Annual Beaumont Health Cardiovascular Conference, held in Beaver Creek, CO, provided cardiology investigators and ... read more
Despite the progress made in the fight against cardiovascular disease in recent decades, stroke and mitigating ... read more
There may soon be a cure for sickle cell disease. A team of investigators, led by Erica ... read more